<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The new calcium <z:chebi fb="68" ids="48706">antagonist</z:chebi> cerebrocrast intravenously infused in a dose of 0.4 micrograms.kg-1.min-1 during 15 min prevented erythrocyte deformability disturbances at the end of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats, which was induced by carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> during 30 min </plain></SENT>
<SENT sid="1" pm="."><plain>The agents also prevented the deformability 1 hour after the <z:hpo ids='HP_0003674'>onset</z:hpo> of recirculation </plain></SENT>
<SENT sid="2" pm="."><plain>Cerebrocrast reduced spontaneous erythrocyte aggregation, the strength of erythrocytic aggregates, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> affinity for oxygen </plain></SENT>
<SENT sid="3" pm="."><plain>The latter effect was associated with the drug-induced increase in erythrocytic <z:chebi fb="0" ids="19324">2,3-diphosphoglycerate</z:chebi> levels </plain></SENT>
</text></document>